Reports and Briefs on Central Nervous System

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | » »|

Type Product title / description Pub Price
Report
Report

Forecast Insight: Fibromyalgia - Regulatory caution threatens EU market expansion

Provides analysis of key events and their impact on the fibromyalgia market over the last year (July 2008June 2009). Includes indication- and country-specific 10-year forecasts of key marketed, generic, and pipeline products to 2018.

Published By Datamonitor
03 Jun 2009 $15200
Buy
Report
Report

Forecast Insight: Attention-Deficit Hyperactivity Disorder - Shire to stay on top despite drug safety fears and generic competition

Provides analysis of key events and their impact on the ADHD market since 2008. Includes an event-based and country-specific 10 year forecast of key marketed, generic, and pipeline products to 2018 in the seven major markets.

Published By Datamonitor
03 Jul 2009 $15200
Buy
Report
Report

Commercial Insight: Antidepressants - Novel mechanism offers hope in depressed market

Analysis of the current and future antidepressant drug class market. Includes sales forecasts to 2018 across the seven major markets (US, Japan, France, Germany, Italy, Spain and the UK) of key marketed brands, generics, and pipeline products.

Published By Datamonitor
08 Oct 2009 $15200
Buy
Report
Report

Commercial Insight: Anticonvulsants - Non-epilepsy label expansions provide blockbuster potential

Analysis of the future potential of anticonvulsants market. Includes sales forecasts over 2009-2018 across the seven major markets (US, Japan, France, Germany, Italy, Spain, and the UK) of key marketed brands, generics, and pipeline agents.

Published By Datamonitor
08 Oct 2009 $15200
Buy
Report
Report

Commercial Insight: Antipsychotics - Revenues of depots and new agents will partially offset generic erosion

Analysis of the current and future antipsychotic market. Includes country-specific sales forecasts to 2018 across the seven major markets (US, Japan, France, Germany, Italy, Spain and the UK) of key marketed brands, generics, and pipeline products.

Published By Datamonitor
28 Oct 2009 $15200
Buy
Report
Report

Stakeholder Opinions: Gene Therapy - Gene therapy to deliver after 20 years of clinical development

Comprehensive analysis of the gene therapy clinical pipeline across all geographic and therapeutic markets, with key opinion leader insights. Identification of drivers and inhibitors to the commercial success of gene therapy.

Published By Datamonitor
10 Dec 2009 $3800
Buy
Report
Report

Stakeholder Opinions: Therapeutic Vaccines - A far-off promise of greatness

This report assesses the current landscape of and future opportunities for therapeutic vaccines outside cancer, covering therapeutic vaccine approaches in cardiovascular and metabolic, CNS, autoimmune and infectious diseases.

Published By Datamonitor
17 Dec 2009 $3800
Buy
Report
Report

Stakeholder Insight: Cancer Pain - Physician survey highlights inadequacies in education and treatment

Datamonitor surveyed 180 oncologists, anesthetists, palliative medicine specialists and pain care specialists in the seven major markets to gain insight into cancer pain prevalence, treatment trends and key prescribing influences.

Published By Datamonitor
23 Dec 2009 $15200
Buy
Report
Report

Stakeholder Opinions: Targeting Nerve Growth Factor for Pain Therapy - Groundbreaking class to breathe new life into saturated market

Assessment of the potential impact of agents targeting nerve growth factor (NGF) for the treatment of pain. Includes analysis of the key market drivers and resistors for this new class based on interviews with key opinion leaders.

Published By Datamonitor
05 Mar 2010 $3800
Buy
Report
Report

Stakeholder Opinions: Spinal Cord Injury - Attractive niche market with multi-billion dollar potential

Analysis of spinal cord injury epidemiology, unmet needs and pipeline treatments. Provides assessment of potential market value and analysis of opportunities and threats facing developers of SCI treatments based on interviews with key opinion leaders

Published By Datamonitor
05 Mar 2010 $3800
Buy

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | » »|

No help is available.